Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 12NET 9Gastrointestinal 4Thoracic 2Sarcoma 1Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 2046Triple Negative Breast Neoplasms 208Neoplasm Metastasis 133Neoplasms 119Carcinoma, Non-Small-Cell Lung 96Breast Neoplasms, Male 95Ovarian Neoplasms 89Colorectal Neoplasms 70Lung Neoplasms 67Carcinoma, Intraductal, Noninfiltrating 63Melanoma 57Prostatic Neoplasms 55Pancreatic Neoplasms 47Breast Carcinoma In Situ 42Stomach Neoplasms 38Colonic Neoplasms 37Brain Neoplasms 36Carcinoma, Renal Cell 35Inflammatory Breast Neoplasms 33Head and Neck Neoplasms 32Urinary Bladder Neoplasms 29Pain 29Small Cell Lung Carcinoma 27Squamous Cell Carcinoma of Head and Neck 26Endometrial Neoplasms 25Sarcoma 23Fatigue 23Uterine Cervical Neoplasms 21Esophageal Neoplasms 21Multiple Myeloma 18

Interventions

Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adenoma, Islet Cell × Breast × Clear all
NCT00428220 2019-06-27

A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Pfizer

Phase NA Completed
223 enrolled 8 charts
BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Adenoma, Islet Cell, Somatostatinoma, Thyroid Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡